EGFR and non-small cell lung carcinoma: A significant proportion of NSCLC patients (approximately 50%) harbor genetic alterations in key oncogenes, including EGFR, KRAS, and ALK, which drive dysregulated cellular metabolism and sustained proliferative signaling [2–4].